argenex SE $ARGX Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in argenex SE (NASDAQ:ARGX) by 1.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,122 shares of the company’s stock after purchasing an additional 1,020 shares during the period. New York State Common Retirement Fund owned approximately 0.11% of argenex worth $48,031,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC increased its position in shares of argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the last quarter. Focus Partners Wealth raised its stake in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of argenex by 2.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 1,171 shares of the company’s stock worth $645,000 after purchasing an additional 30 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ARGX. Royal Bank Of Canada lifted their target price on shares of argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. TD Cowen lifted their price objective on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. Morgan Stanley raised their target price on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Finally, Zacks Research lowered shares of argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average price target of $986.78.

argenex Price Performance

ARGX opened at $840.50 on Friday. The business has a fifty day moving average price of $852.12 and a 200 day moving average price of $781.37. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a market capitalization of $52.01 billion, a price-to-earnings ratio of 36.09, a PEG ratio of 0.56 and a beta of 0.38.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. On average, research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.